行情

SNDX

SNDX

Syndax
NASDAQ

实时行情|Nasdaq Last Sale

6.91
+0.16
+2.37%
盘后: 6.62 -0.29 -4.20% 16:00 11/15 EST
开盘
6.79
昨收
6.75
最高
6.95
最低
6.70
成交量
7.11万
成交额
--
52周最高
11.11
52周最低
3.390
市值
1.88亿
市盈率(TTM)
-3.2763
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SNDX 新闻

  • 花旗策略师:美股明年面临四大障碍
  • 新浪美股.4小时前
  • 三大指数提供商最快在12月将沙特阿美纳入其指数
  • 新浪美股.6小时前
  • 日韩企业联手 韩媒:将对阿里腾讯构成巨大威胁
  • 参考消息.8小时前
  • 外媒:流媒体平台如何改变人们看电视的方式
  • 参考消息.8小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

SNDX 简况

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
展开

Webull提供Syndax Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。